Cantor Fitzgerald Predicts Increased Earnings for Omeros

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share estimate for Omeros to ($1.69), up from a previous forecast of ($2.14), while the consensus estimate for the full year is ($3.09) per share.
• Omeros reported earnings of ($0.53) per share for the last quarter, slightly exceeding analysts' expectations, with revenue of $28.60 million compared to a consensus estimate of $0.31 million.
• The stock's current market capitalization is approximately $269.28 million with shares opening at $4.36, reflecting a 3.3% increase.

Omeros Corporation (NASDAQ:OMER - Free Report) - Analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Omeros in a research note issued to investors on Monday, August 18th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of ($1.69) for the year, up from their prior forecast of ($2.14). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros' FY2026 earnings at ($0.97) EPS.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million.

A number of other equities research analysts have also commented on OMER. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Omeros in a research report on Friday, June 27th. Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. D. Boral Capital restated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Friday, August 15th. Finally, Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Omeros Stock Performance

Shares of NASDAQ:OMER traded down $0.0010 during midday trading on Wednesday, reaching $4.3990. The company had a trading volume of 404,055 shares, compared to its average volume of 916,339. Omeros has a 1-year low of $2.95 and a 1-year high of $13.60. The firm has a market cap of $299.40 million, a price-to-earnings ratio of -2.09 and a beta of 2.26. The company has a fifty day simple moving average of $3.66 and a two-hundred day simple moving average of $5.59.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 1,110 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Omeros by 4.9% in the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock valued at $345,000 after acquiring an additional 1,973 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Omeros by 2.0% in the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock valued at $1,190,000 after acquiring an additional 2,317 shares in the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock valued at $286,000 after acquiring an additional 2,600 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.